Bio Blast Pharma Ltd. is a clinical-stage biotechnology company. It engages in developing therapies for patients with rare and ultra-rare genetic diseases. Bio Blast products include Cabaletta to treat oculopharyngeal muscular dystrophy, Machado Joseph disease or SCA3, and Kennedy's disease or SBMA; BBrm to treat diseases caused by nonsense mutation; and mPRT to treat mitochondrial protein deficiency diseases. The Company offers its products to the healthcare and medical industries. Bio Blast Pharma Ltd. is headquartered in Tel Aviv, Israel.